Below are the most recent publications written about "Rhabdomyosarcoma" by people in Profiles.
-
Whittle S, Venkatramani R, Schönstein A, Pack SD, Alaggio R, Vokuhl C, Rudzinski ER, Wulf AL, Zin A, Gruver JR, Arnold MA, Merks JHM, Hettmer S, Koscielniak E, Barr FG, Hawkins DS, Bisogno G, Sparber-Sauer M. Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. Eur J Cancer. 2022 06; 168:56-64.
-
Zhang X, Wang S, Rudzinski ER, Agarwal S, Rong R, Barkauskas DA, Daescu O, Furman Cline L, Venkatramani R, Xie Y, Xiao G, Leavey P. Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction. Am J Pathol. 2022 Jun; 192(6):917-925.
-
Crane JN, Xue W, Qumseya A, Gao Z, Arndt CAS, Donaldson SS, Harrison DJ, Hawkins DS, Linardic CM, Mascarenhas L, Meyer WH, Rodeberg DA, Rudzinski ER, Shulkin BL, Walterhouse DO, Venkatramani R, Weiss AR. Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Pediatr Blood Cancer. 2022 06; 69(6):e29644.
-
Haduong JH, Heske CM, Allen-Rhoades W, Xue W, Teot LA, Rodeberg DA, Donaldson SS, Weiss A, Hawkins DS, Venkatramani R. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022 04; 69(4):e29511.
-
Nakahata K, Simons BW, Pozzo E, Shuck R, Kurenbekova L, Prudowsky Z, Dholakia K, Coarfa C, Patel TD, Donehower LA, Yustein JT. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. Dis Model Mech. 2022 02 01; 15(2).
-
Aye JM, Venkatramani R. Comment on: Patients with nonmetastatic embryonal rhabdomyosarcoma arising in the biliary tract should be treated on low-risk clinical trials. Pediatr Blood Cancer. 2022 07; 69(7):e29554.
-
Russell HV, Chi YY, Okcu MF, Bernhardt MB, Rodriguez-Galindo C, Gupta AA, Hawkins DS. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15; 128(2):317-325.
-
Wang L, Hensch NR, Bondra K, Sreenivas P, Zhao XR, Chen J, Moreno Campos R, Baxi K, Vaseva AV, Sunkel BD, Gryder BE, Pomella S, Stanton BZ, Zheng S, Chen EY, Rota R, Khan J, Houghton PJ, Ignatius MS. SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation. Cancer Res. 2021 11 01; 81(21):5451-5463.
-
Sobel RK, Ford JR, Dong W, Shriver E, Griepentrog GJ, Debnam JM, Esmaeli B. Frequency and Clinical Course of Residual Orbital Masses After Treatment of Orbital Rhabdomyosarcoma. Am J Ophthalmol. 2022 02; 234:28-36.
-
Ting MA, Reuther J, Chandramohan R, Voicu H, Gandhi I, Liu M, Cortes-Santiago N, Foster JH, Hicks J, Nuchtern J, Scollon S, Plon SE, Chintagumpala M, Rainusso N, Roy A, Parsons DW. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.